144 related articles for article (PubMed ID: 38097300)
1. Treat All versus targeted strategies to select HBV-infected people for antiviral therapy in The Gambia, west Africa: a cost-effectiveness analysis.
Nguyen LBL; Lemoine M; Ndow G; Ward ZJ; Hallet TB; D'Alessandro U; Thursz M; Nayagam S; Shimakawa Y
Lancet Glob Health; 2024 Jan; 12(1):e66-e78. PubMed ID: 38097300
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of community-based screening and treatment for chronic hepatitis B in The Gambia: an economic modelling analysis.
Nayagam S; Conteh L; Sicuri E; Shimakawa Y; Suso P; Tamba S; Njie R; Njai H; Lemoine M; Hallett TB; Thursz M
Lancet Glob Health; 2016 Aug; 4(8):e568-78. PubMed ID: 27443782
[TBL] [Abstract][Full Text] [Related]
3. Impact and cost-effectiveness of hepatitis B virus prophylaxis in pregnancy: a dynamic simulation modelling study.
Nayagam S; de Villiers MJ; Shimakawa Y; Lemoine M; Thursz MR; Walsh N; Hallett TB
Lancet Gastroenterol Hepatol; 2023 Jul; 8(7):635-645. PubMed ID: 37150181
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness of Testing and Treatment for Hepatitis B Virus and Hepatitis C Virus Infections: An Analysis by Scenarios, Regions, and Income.
Tordrup D; Hutin Y; Stenberg K; Lauer JA; Hutton DW; Toy M; Scott N; Chhatwal J; Ball A
Value Health; 2020 Dec; 23(12):1552-1560. PubMed ID: 33248510
[TBL] [Abstract][Full Text] [Related]
5. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
Shepherd J; Jones J; Takeda A; Davidson P; Price A
Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
[TBL] [Abstract][Full Text] [Related]
6. Development and evaluation of a simple treatment eligibility score (HEPSANET) to decentralise hepatitis B care in Africa: a cross-sectional study.
Minier N; Guingané AN; Okeke E; Sinkala E; Johannessen A; Andersson MI; Davwar P; Desalegn H; Duguru M; Fall F; Mboup S; Maponga T; Matthews PC; Ramírez Mena A; Ndow G; Orlien SMS; Riches N; Seydi M; Sonderup M; Spearman CW; Stockdale AJ; Taljaard J; Vinikoor M; Wandeler G; Lemoine M; Shimakawa Y; Sombié R
Lancet Gastroenterol Hepatol; 2024 Apr; 9(4):323-332. PubMed ID: 38367633
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of different monitoring strategies in a screening and treatment programme for hepatitis B in The Gambia.
Schmit N; Nayagam S; Lemoine M; Ndow G; Shimakawa Y; Thursz MR; Hallett TB
J Glob Health; 2023 Jan; 13():04004. PubMed ID: 36655869
[TBL] [Abstract][Full Text] [Related]
8. Prevention of hepatitis B mother-to-child transmission in Namibia: A cost-effectiveness analysis.
Tamandjou Tchuem CR; Andersson MI; Wiysonge CS; Mufenda J; Preiser W; Cleary S
Vaccine; 2021 May; 39(23):3141-3151. PubMed ID: 33962836
[TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics and outcomes of patients with cirrhosis and hepatocellular carcinoma in The Gambia, west Africa: a prospective cohort study.
Ndow G; Vo-Quang E; Shimakawa Y; Ceesay A; Tamba S; Njai HF; Bojang L; Hateley C; Takao Y; Opoku E; Warsop Z; Ingiliz P; D'Alessandro U; Chemin I; Mendy M; Thursz M; Njie R; Lemoine M
Lancet Glob Health; 2023 Sep; 11(9):e1383-e1392. PubMed ID: 37517420
[TBL] [Abstract][Full Text] [Related]
10. Acceptability and feasibility of a screen-and-treat programme for hepatitis B virus infection in The Gambia: the Prevention of Liver Fibrosis and Cancer in Africa (PROLIFICA) study.
Lemoine M; Shimakawa Y; Njie R; Taal M; Ndow G; Chemin I; Ghosh S; Njai HF; Jeng A; Sow A; Toure-Kane C; Mboup S; Suso P; Tamba S; Jatta A; Sarr L; Kambi A; Stanger W; Nayagam S; Howell J; Mpabanzi L; Nyan O; Corrah T; Whittle H; Taylor-Robinson SD; D'Alessandro U; Mendy M; Thursz MR;
Lancet Glob Health; 2016 Aug; 4(8):e559-67. PubMed ID: 27443781
[TBL] [Abstract][Full Text] [Related]
11. Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models.
Eaton JW; Menzies NA; Stover J; Cambiano V; Chindelevitch L; Cori A; Hontelez JA; Humair S; Kerr CC; Klein DJ; Mishra S; Mitchell KM; Nichols BE; Vickerman P; Bakker R; Bärnighausen T; Bershteyn A; Bloom DE; Boily MC; Chang ST; Cohen T; Dodd PJ; Fraser C; Gopalappa C; Lundgren J; Martin NK; Mikkelsen E; Mountain E; Pham QD; Pickles M; Phillips A; Platt L; Pretorius C; Prudden HJ; Salomon JA; van de Vijver DA; de Vlas SJ; Wagner BG; White RG; Wilson DP; Zhang L; Blandford J; Meyer-Rath G; Remme M; Revill P; Sangrujee N; Terris-Prestholt F; Doherty M; Shaffer N; Easterbrook PJ; Hirnschall G; Hallett TB
Lancet Glob Health; 2014 Jan; 2(1):e23-34. PubMed ID: 25104632
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of universal screening for chronic hepatitis B virus infection in China: an economic evaluation.
Su S; Wong WC; Zou Z; Cheng DD; Ong JJ; Chan P; Ji F; Yuen MF; Zhuang G; Seto WK; Zhang L
Lancet Glob Health; 2022 Feb; 10(2):e278-e287. PubMed ID: 35063115
[TBL] [Abstract][Full Text] [Related]
13. Cost and cost-effectiveness of a universal HIV testing and treatment intervention in Zambia and South Africa: evidence and projections from the HPTN 071 (PopART) trial.
Thomas R; Probert WJM; Sauter R; Mwenge L; Singh S; Kanema S; Vanqa N; Harper A; Burger R; Cori A; Pickles M; Bell-Mandla N; Yang B; Bwalya J; Phiri M; Shanaube K; Floyd S; Donnell D; Bock P; Ayles H; Fidler S; Hayes RJ; Fraser C; Hauck K;
Lancet Glob Health; 2021 May; 9(5):e668-e680. PubMed ID: 33721566
[TBL] [Abstract][Full Text] [Related]
14. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness and budget impact of the community-based management of hypertension in Nepal study (COBIN): a retrospective analysis.
Krishnan A; Finkelstein EA; Kallestrup P; Karki A; Olsen MH; Neupane D
Lancet Glob Health; 2019 Oct; 7(10):e1367-e1374. PubMed ID: 31537367
[TBL] [Abstract][Full Text] [Related]
16. [Cost-effectiveness of community-based treatment of chronic hepatitis B in China].
Zhang SX; Yang PC; Cai YL; Lin Y; Zou YH
Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Jul; 38(7):860-867. PubMed ID: 28738456
[No Abstract] [Full Text] [Related]
17. Active Tuberculosis Screening via a Mobile Health App in Myanmar: Incremental Cost-Effectiveness Evaluation.
Htet KKK; Phyu AN; Zayar NN; Chongsuvivatwong V
JMIR Form Res; 2023 Nov; 7():e51998. PubMed ID: 37948119
[TBL] [Abstract][Full Text] [Related]
18. Moving towards malaria elimination in southern Mozambique: Cost and cost-effectiveness of mass drug administration combined with intensified malaria control.
Cirera L; Galatas B; Alonso S; Paaijmans K; Mamuquele M; Martí-Soler H; Guinovart C; Munguambe H; Luis F; Nhantumbo H; Montañà J; Bassat Q; Candrinho B; Rabinovich R; Macete E; Aide P; Alonso P; Saúte F; Sicuri E
PLoS One; 2020; 15(7):e0235631. PubMed ID: 32628741
[TBL] [Abstract][Full Text] [Related]
19. Cost and cost-effectiveness of a real-world HCV treatment program among HIV-infected individuals in Myanmar.
Marquez LK; Chaillon A; Soe KP; Johnson DC; Zosso JM; Incerti A; Loarec A; Nguyen A; Walker JG; Mafirakureva N; Lo Re Iii V; Wynn A; McIntosh C; Kiene SM; Brodine S; Garfein RS; Vickerman P; Martin NK
BMJ Glob Health; 2021 Feb; 6(2):. PubMed ID: 33627360
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of adding a birth dose of hepatitis B vaccine in the Dafra district of the Hauts-Bassins Region in Burkina Faso (NéoVac Study).
Gosset A; Diallo MY; Betsem E; Schaeffer L; Meda N; Vray M; Sombie R; Shimakawa Y; Boyer S
Vaccine; 2021 Jul; 39(33):4659-4670. PubMed ID: 34238606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
